目的 探讨解郁除烦胶囊联合帕罗西汀治疗抑郁症心境障碍的临床疗效。方法 纳入2023年5月—2025年5月秦皇岛市九龙山医院收治的202例抑郁症心境障碍患者，根据随机数字表法分为对照组和治疗组，每组各101例。对照组口服盐酸帕罗西汀片，早晨顿服20 mg/次，1次/d。在此基础上，治疗组口服解郁除烦胶囊，4粒/次，3次/d，早、中、晚3个时间段规律用药。两组均治疗8周。比较两组临床疗效、治疗前和治疗4、8周后汉密尔顿抑郁量表（HAMD-17）积分，治疗前后临床总体印象-病情严重程度量表（CGI-SI）、哥伦比亚自杀严重程度量表（C-SSRS）、简明幸福与生活质量满意度问卷（Q-LES-Q-SF）评分及中性粒细胞与淋巴细胞比值（NLR）和血清白细胞介素-1β（IL-1β）、5-羟色胺（5-HT）、神经肽Y（NPY）水平。结果 治疗后，治疗组总有效率（95.05%）较对照组（87.13%）更高（P＜0.05）。治疗4周、8周后，两组HAMD-17积分均明显降低（P＜0.05），且治疗组以上时间点的HAMD-17积分均低于同期对照组（P＜0.05）。治疗后，两组CGI-SI、C-SSRS评分减少（P＜0.05），Q-LES-Q-SF评分增加（P＜0.05）；治疗组上述评分均优于对照组（P＜0.05）。治疗后，两组NLR及血清IL-1β水平下降（P＜0.05），而血清5-HT、NPY水平升高（P＜0.05）；治疗组上述血清细胞因子水平均优于对照组（P＜0.05）。结论 解郁除烦胶囊联合帕罗西汀治疗抑郁症心境障碍，能抑制神经炎症及神经递质紊乱，促进抑郁程度减轻，有利于整体病情及自杀风险控制，对生活质量的满意度得到有效改善。

Objective To explore the clinical efficacy of Jieyu Chufan Capsule combined with paroxetine in treating depressive mood disorders. Methods A total of 202 patients with depressive mood disorders admitted to Qinhuangdao Jiulongshan Hospital from May 2023 to May 2025 were enrolled and divided into a control group and a treatment group using a random number table method, with 101 cases in each group. Patients in the control group were po administered with Paroxetine Hydrochloride Tablets, 20 mg once daily in the morning. On this basis, patients in the treatment group were po administered with Jieyu Chufan Capsules, 4 capsules three times daily (morning, noon, and evening). Both groups were treated for 8 weeks. The clinical efficacy, Hamilton Depression Scale-17 (HAMD-17) scores before treatment and at 4 and 8 weeks after treatment, Clinical Global Impressions-Severity of Illness Scale (CGI-SI), Columbia-Suicide Severity Rating Scale (C-SSRS), Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) scores before and after treatment, as well as neutrophil-to-lymphocyte ratio (NLR) and serum levels of interleukin-1β (IL-1β), 5-hydroxytryptamine (5-HT), and neuropeptide Y (NPY) were compared between the two groups. Results After treatment, the total effective rate in the treatment group [95.05% (96/101)] was higher than that in the control group [87.13% (88/101)] (P < 0.05). At 4 and 8 weeks after treatment, HAMD-17 scores were significantly reduced in both groups (P< 0.05), and the HAMD-17 scores in the treatment group at these time points were lower than those in the control group at the same time points (P< 0.05). After treatment, CGI-SI and C-SSRS scores decreased (P < 0.05), and Q-LES-Q-SF scores increased (P < 0.05) in both groups. The scores in the treatment group were better than those in the control group (P< 0.05). After treatment, NLR and serum IL-1β levels decreased (P< 0.05), while serum 5-HT and NPY levels increased (P < 0.05) in both groups; the levels of these serum cytokines in the treatment group were better than those in the control group (P < 0.05). Conclusion Jieyu Chufan Capsules combined with paroxetine in treatment of depressive mood disorders can inhibit neuroinflammation and neurotransmitter disorders, reduce the severity of depression, help control overall disease condition and suicide risk, and effectively improve satisfaction with quality of life.

秦皇岛市重点研发计划科技支撑项目（202301A041）